Workpackage 4

Documents for Download

Created by: Hellenbrecht (ELIC) , generated 2006/11/27, last changed: 2008/07/24

Registry for long-term follow-up of CML patients who discontinued Imatinib after Complete Cytogenetic Response

for the registry on patients who discontinued imatinib after CCR
(Baseline) time of diagnosis
(Discontinuation of Imatinib) to be filled out at time of 1st discontinuation of Imatinib and every 3 months thereafter
(Discontinuation of Imatinib) to be filled out at time of 1st discontinuation of Imatinib and every 3 months thereafter
(Restart of Imatinib) (to be filled out at time of 1st restart of Imatinib and every 3 months thereafter)
(Therapeutic responses before the 1st disc. of I.) to be filled out every 3 months after diagnosis, but only as long as Imatinib was administered, otherwise refer to the 2nd Form

 

Print this Document   Sitemap   Contact  
EUTOS
EUTOS for CML is a unique collaboration between the European LeukemiaNet and Novartis Oncology in Europe More ...


 
top